Mar 13, 2024 05:15PM
Mar 6, 2024 02:45PM
Feb 26, 2024 07:38PM
Feb 8, 2024 04:35PM
Jan 2, 2024 05:40PM
Oct 16, 2023 05:23PM
Sep 14, 2023 05:00PM Intellipharmaceutics Reports Director Election Results
Jul 14, 2023 04:05PM
Oct 14, 2022 04:15PM
Aug 16, 2022 08:00AM
Jul 21, 2022 02:50PM
Jul 15, 2022 08:00AM
May 27, 2022 04:45PM
Apr 14, 2022 04:30PM Intellipharmaceutics Announces First Quarter 2022 Results
Feb 28, 2022 05:25PM
Feb 4, 2022 04:35PM
Jan 13, 2022 05:20PM
Dec 22, 2021 01:00PM
Oct 15, 2021 05:20PM
Apr 22, 2021 07:50AM
Apr 14, 2021 07:45AM Intellipharmaceutics Announces First Quarter 2021 Results
Mar 1, 2021 08:15AM
Dec 23, 2020 04:45PM
Dec 15, 2020 05:30PM
Jul 15, 2020 05:25PM
Jul 2, 2020 11:00AM
May 29, 2020 05:20PM
Apr 9, 2020 06:55PM Intellipharmaceutics Provides Timing of First Quarter 2020 Results
Feb 28, 2020 04:30PM
Feb 5, 2020 04:45PM
Jan 16, 2020 08:00AM
Dec 5, 2019 09:30AM
Nov 25, 2019 04:35PM
Nov 18, 2019 04:30PM
Oct 24, 2019 01:40PM Intellipharmaceutics Update on its Oxycodone ER New Drug Application
Oct 11, 2019 05:15PM
Sep 5, 2019 01:33PM
Aug 15, 2019 03:15PM
Jul 24, 2019 05:00PM
Jul 10, 2019 05:00PM
Jul 8, 2019 05:10PM
May 30, 2019 08:45AM Intellipharmaceutics Announces Receipt of Cannabis Drug License from Health Canada
May 29, 2019 05:00PM
May 29, 2019 09:30AM
May 10, 2019 01:00PM
May 7, 2019 06:15PM
Apr 25, 2019 06:30PM
Apr 15, 2019 04:15PM
Mar 29, 2019 08:00AM U.S. FDA Acknowledges Receipt of Intellipharmaceutics' Resubmission of Oxycodone ER New Drug Application, Deems it a Complete Response, and Designates August 28, 2019 as Goal Date for Review

322,337 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All